Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Mario E. Lacouture, Milan J. Anadkat, René Jean Bensadoun, Jane Bryce, Alexandre Chan, Joel B. Epstein, Beth Eaby-Sandy, Barbara A. Murphy

Research output: Contribution to journalReview article

Abstract

Background: Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities. Methods: A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities. Results: Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible. Conclusion: Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients' health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.

Original languageEnglish
Pages (from-to)1079-1095
Number of pages17
JournalSupportive Care in Cancer
Volume19
Issue number8
DOIs
Publication statusPublished - 2011

Keywords

  • EGFR inhibitors
  • Mucositis
  • Paronychia
  • Pruritus
  • Radiation dermatitis
  • Rash
  • Recommendations
  • Xerosis

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology

Fingerprint Dive into the research topics of 'Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities'. Together they form a unique fingerprint.

  • Cite this

    Lacouture, M. E., Anadkat, M. J., Bensadoun, R. J., Bryce, J., Chan, A., Epstein, J. B., Eaby-Sandy, B., & Murphy, B. A. (2011). Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supportive Care in Cancer, 19(8), 1079-1095. https://doi.org/10.1007/s00520-011-1197-6